ATXS — Astria Therapeutics Share Price
0.000.00%
Last trade - 00:00- $227.99m
- -$4.81m
- 28
- 29
- 27
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.51% | ||
| Return on Equity | -50.71% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.25 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Directors
- Kenneth Bate NEC (70)
- Jill Milne PRE (53)
- Noah Clauser CFO (48)
- Andrew Nichols CSO (60)
- Benjamin Harshbarger GCN (52)
- Andrew Komjathy OTH (58)
- Jonathan Violin DRC
- Joanne Beck IND (60)
- Fred Callori IND (53)
- Hugh Cole IND (56)
- Michael Kishbauch IND (72)
- Gregg Lapointe IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 26th, 2008
- Public Since
- June 25th, 2015
- No. of Shareholders
- 19
- No. of Employees
- 78
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 56,434,219
- Address
- 22 Boston Wharf Road, 10Th Floor, BOSTON, 02210
- Web
- https://astriatx.com/
- Phone
- +1 6173491971
- Contact
- Elizabeth Higgins
- Auditors
- Ernst & Young LLP
Upcoming Events for ATXS
Astria Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Astria Therapeutics Inc Earnings Release
Similar to ATXS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Astria Therapeutics share price?
As of Today at 19:24 UTC, shares in Astria Therapeutics are trading at $4.04. This share price information is delayed by 15 minutes.
How has the Astria Therapeutics share price performed this year?
Shares in Astria Therapeutics last closed at $4.04 and the price had moved by -61.71% over the past 365 days. In terms of relative price strength the Astria Therapeutics share price has underperformed the S&P500 Index by -63.99% over the past year.
What are the analyst and broker recommendations for Astria Therapeutics?
The overall consensus recommendation for Astria Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Astria Therapeutics dividend yield?
Astria Therapeutics does not currently pay a dividend.
Does Astria Therapeutics pay a dividend?
Astria Therapeutics does not currently pay a dividend.
When does Astria Therapeutics next pay dividends?
Astria Therapeutics does not currently pay a dividend.
How do I buy Astria Therapeutics shares?
To buy shares in Astria Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Astria Therapeutics?
As of the previous close price of $4.04, shares in Astria Therapeutics had a market capitalisation of $227.99m.
Where are Astria Therapeutics shares listed?
Here are the trading details for Astria Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ATXS
What kind of share is Astria Therapeutics?
Based on an overall assessment of its quality, value and momentum Astria Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Astria Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Astria Therapeutics is $26.50. That is 555.94% above the last closing price of $4.04.
Analysts covering Astria Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.92 for the next financial year.
Find out moreWhat is the trend in the Astria Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Astria Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -60.93%.
As of the last closing price of $4.04, shares in Astria Therapeutics were trading -56.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Astria Therapeutics PE Ratio?
The Astria Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Astria Therapeutics?
Astria Therapeutics' management team is headed by:
- Kenneth Bate - NEC
- Jill Milne - PRE
- Noah Clauser - CFO
- Andrew Nichols - CSO
- Benjamin Harshbarger - GCN
- Andrew Komjathy - OTH
- Jonathan Violin - DRC
- Joanne Beck - IND
- Fred Callori - IND
- Hugh Cole - IND
- Michael Kishbauch - IND
- Gregg Lapointe - IND